Buy VISCODERM® SKINKÒ E + VISCODERM® SKINKÒ KIT Online

VISCODERM® SKINKÒ E and VISCODERM® SKINKÒ KIT Indications for Use

VISCODERM® SKINKÒ E and VISCODERM® SKINKÒ KIT are injectable, reabsorbable implants designed for skin rejuvenation and anti-aging treatments. They are used to reduce the appearance of fine lines, wrinkles, and to improve skin hydration and overall skin quality.

• VISCODERM® SKINKÒ E: Contains a higher concentration of hyaluronic acid (32 mg) and is indicated for areas with wrinkles and fine lines, particularly around the eyes (periorbital) and mouth (perioral).
• VISCODERM® SKINKÒ: Contains 2 mg of hyaluronic acid and is used primarily for improving hydration and addressing fine lines.

Both products can be injected into the superficial and middle dermis and are suitable for healthy patients. The choice between the two products is left to the discretion of the practitioner based on the patient’s skin condition.

VISCODERM® SKINKÒ E and VISCODERM® SKINKÒ KIT Dosage Information

The dosage for VISCODERM® SKINKÒ E and VISCODERM® SKINKÒ depends on the area treated and the desired results.

• VISCODERM® SKINKÒ: Contains 2 mg of hyaluronic acid per 5 ml vial, used for hydration and fine line treatment.
• VISCODERM® SKINKÒ E: Contains 32 mg of hyaluronic acid per 5 ml vial, used for wrinkle and fine line reduction, with a slight volume-enhancing effect.

Initial Treatment:

• For optimal results, three sessions are recommended, spaced one week apart.
• Maintenance treatments may be scheduled monthly, depending on the patient’s individual skin needs.

VISCODERM® SKINKÒ E and VISCODERM® SKINKÒ KIT Side Effects and Precautions

While VISCODERM® SKINKÒ and VISCODERM® SKINKÒ E are generally safe, patients may experience some side effects following treatment. Practitioners should ensure patients are informed about possible reactions and precautions.

• Common Side Effects:
  • Redness, swelling, or slight inflammation at the injection site, which should resolve within 24-48 hours.
  • Mild edema and bruising are also common and should subside within 48 hours.
• Serious Side Effects:
  • Nodules or lumps at the injection site.
  • Bleeding during the procedure.

VISCODERM® SKINKÒ E and VISCODERM® SKINKÒ KIT Precautions:

• Avoid using in patients with hypersensitivity to any of the product’s components.
• Do not use on patients with autoimmune disorders, ongoing immunotherapy, or chronic skin diseases.
• Pregnant and breastfeeding women should avoid this treatment.
• Patients with bleeding disorders or those taking anticoagulants should consult their physician prior to treatment.

Clinical Studies or Real-World Outcomes

Clinical studies demonstrate that VISCODERM® SKINKÒ E and VISCODERM® SKINKÒ are effective in reducing wrinkles and improving skin hydration. The results are noticeable after the first treatment, with optimal effects seen after three sessions.

• Patient Satisfaction: Patients report smoother, more hydrated skin, with a significant reduction in fine lines and wrinkles.
• Long-lasting effects: With maintenance treatments, the results can last several months, depending on individual skin conditions.

VISCODERM® SKINKÒ E and VISCODERM® SKINKÒ KIT Drug Interactions

There are no known significant drug interactions with VISCODERM® SKINKÒ or VISCODERM® SKINKÒ E. However, practitioners should proceed with caution when combining these treatments with other skin procedures.

• Avoid simultaneous use with other products containing quaternary ammonium salts such as Benzalkonium Chloride, as this may cause hyaluronic acid precipitation.
• Caution should be taken when treating areas previously injected with other permanent fillers.

VISCODERM® SKINKÒ E and VISCODERM® SKINKÒ KIT Contraindications

Patients should not receive VISCODERM® SKINKÒ E or VISCODERM® SKINKÒ injections if they have the following conditions:

• Known hypersensitivity or allergy to any ingredients.
• Active skin infections or skin damage at the treatment site.
• Autoimmune diseases or a history of autoimmune reactions.
• Pregnancy or breastfeeding.
• Individuals under 18 years of age.

Administration and Usage Guidelines

VISCODERM® SKINKÒ and VISCODERM® SKINKÒ E should only be administered by a qualified practitioner. Proper aseptic techniques must be followed during the injection process to avoid contamination.

• Before treatment:
  • The treatment area should be thoroughly cleaned with antiseptic solutions, avoiding products containing chlorhexidine or quaternary ammonium salts.
  • Local anesthetic can be applied, particularly when treating sensitive areas such as the perioral region.
• Injection Techniques:
  • VISCODERM® SKINKÒ is typically injected using techniques such as nappage, papules, or point-by-point injection methods.
  • VISCODERM® SKINKÒ E can be administered using techniques like retrotracing, fan injection, or cross-hatching.

VISCODERM® SKINKÒ E and VISCODERM® SKINKÒ KIT Post-Treatment Care

After the injection, patients should follow specific post-care instructions to ensure the best results and reduce the risk of complications:

• Avoid prolonged sun exposure, UV rays, frost, and extreme heat (e.g., saunas) for at least two weeks after treatment.
• Use sunscreen with a high SPF to protect the treated areas.
• Patients should not apply makeup for 12 hours after treatment.
• Avoid massaging or pressing the treated area for 3-5 days to allow the product to settle.